Medication info

Locatroll Soft Capsule 0.25 Micrograms (Calcitriol)

Prescription medicationSoft capsuleApproval withdrawn
Ingredient · strength
Calcitriol›0.25μg
Manufacturer / importer
ZP Therapeutics Korea Co., Ltd.
Appearance
Orange on top and white on the bottom, oval soft capsule
Packaging
30 capsules (10 capsules/PTP packaging x 3)
Approval status
Approval withdrawn

MFDS item code 200610653 · Notified 2006.07.18

This product's status changed to Approval withdrawn on 2025.09.16. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of bone disorders (renal bone disease, rickets, osteoporosis, etc.) and parathyroid dysfunction
Who uses it
Adults · Children
Adult dosage
The optimal daily dose of this medicine should be carefully determined for each patient based on serum calcium levels. Start treatment at the lowest possible dose and do not increase the dose without close monitoring of serum calcium. ○ Patients before the dialysis stage: The adult dose is 0.25 ㎍ of calcitriol daily and may be increased to 0.5 ㎍ daily if necessary. ○ Renal osteodystrophy (dialysis patients): The initial daily dose is 0.25 ㎍ of this medicine. Patients with serum calcium levels in the normal range or slightly below normal should receive 0.25 ㎍ every other day. If there is not an adequate response in biochemical test results and clinical symptoms, increase the dose by 0.25 ㎍ daily at intervals of 2 ~ 4 weeks. During this period, serum calcium levels should be measured at least twice weekly. Most patients respond to doses of 0.5 ~ 1.0 ㎍ daily. This medicine improves calcium absorption from the gastrointestinal tract, so some patients taking it may be maintained on a lower calcium intake. In patients prone to hypercalcemia, a small amount of calcium may be sufficient, or calcium supplementation may not be needed at all. ○ Osteoporosis: Administer 0.25 ㎍ of this medicine twice daily. During dose stabilization, serum calcium levels should be measured at least twice weekly. If hypercalcemia is observed, discontinue treatment until serum calcium levels return to normal. Because this medicine increases calcium absorption in postmenopausal patients with osteoporosis, calcium supplementation may not be necessary. ○ Hypoparathyroidism and rickets/osteomalacia: The recommended initial dose is 0.25 ㎍ of this medicine each morning. If there is not an adequate response in biochemical test results and clinical symptoms, increase the dose at intervals of 2 ~ 4 weeks. During dose determination, serum calcium levels should be measured at least twice weekly. Malabsorption sometimes occurs in patients with hypoparathyroidism, so higher doses may be necessary. ○ General information: After the optimal dose of this medicine has been determined, serum calcium levels should be measured once monthly. Blood samples for serum calcium measurement should be collected without a tourniquet. If serum calcium rises by 1 mg/dL (250 μmol/L) above the normal range of 9 ~ 11 mg/dL (2,250 ~ 2,750 μmol/L), or serum creatinine rises to 120 μmol/L or higher, promptly reduce the dose sufficiently or discontinue treatment until serum calcium returns to normal. Discontinuing supplemental calcium is also effective for rapidly normalizing serum calcium. Carefully consider reducing dietary calcium intake as well. During hypercalcemia, serum calcium and phosphorus levels should be measured daily. Once levels return to normal, continue treatment at a dose 0.25 ㎍ lower per day than the previous dose.
Children's dosage
○ Patients before the dialysis stage, children aged 36 months or older: The dose is 0.25 ㎍ of calcitriol daily and may be increased to 0.5 ㎍ daily if necessary. ○ Patients before the dialysis stage, children under 36 months: The recommended initial dose is 10 ~ 15 ng per kg of body weight daily.

Ingredients

Importer
ZP Therapeutics Korea Co., Ltd.

Efficacy & effects

Treatment of bone disorders (renal bone disease, rickets, osteoporosis, etc.) and parathyroid dysfunction

  • Chronic kidney failure
  • secondary hyperparathyroidism
  • metabolic bone disease
  • renal osteodystrophy
  • hypoparathyroidism
  • rickets
  • osteomalacia
  • osteoporosis
View approved original text

This medication is used for the treatment of secondary hyperparathyroidism and associated metabolic bone disease in patients with chronic kidney failure before dialysis. It also helps improve renal osteodystrophy in patients undergoing hemodialysis. It is also used in the treatment of hypoparathyroidism (post-surgical, idiopathic or pseudo). It is effective for rickets and osteomalacia, particularly vitamin D-dependent rickets and hypophosphatemic vitamin D-resistant rickets. Furthermore, it is used for the management of osteoporosis. In summary, it is effectively used for various bone-related conditions such as chronic kidney failure, hypoparathyroidism, rickets, osteomalacia, and osteoporosis.

Dosage and Administration

Adult dosage

The optimal daily dose of this medicine should be carefully determined for each patient based on serum calcium levels. Start treatment at the lowest possible dose and do not increase the dose without close monitoring of serum calcium. ○ Patients before the dialysis stage: The adult dose is 0.25 ㎍ of calcitriol daily and may be increased to 0.5 ㎍ daily if necessary. ○ Renal osteodystrophy (dialysis patients): The initial daily dose is 0.25 ㎍ of this medicine. Patients with serum calcium levels in the normal range or slightly below normal should receive 0.25 ㎍ every other day. If there is not an adequate response in biochemical test results and clinical symptoms, increase the dose by 0.25 ㎍ daily at intervals of 2 ~ 4 weeks. During this period, serum calcium levels should be measured at least twice weekly. Most patients respond to doses of 0.5 ~ 1.0 ㎍ daily. This medicine improves calcium absorption from the gastrointestinal tract, so some patients taking it may be maintained on a lower calcium intake. In patients prone to hypercalcemia, a small amount of calcium may be sufficient, or calcium supplementation may not be needed at all. ○ Osteoporosis: Administer 0.25 ㎍ of this medicine twice daily. During dose stabilization, serum calcium levels should be measured at least twice weekly. If hypercalcemia is observed, discontinue treatment until serum calcium levels return to normal. Because this medicine increases calcium absorption in postmenopausal patients with osteoporosis, calcium supplementation may not be necessary. ○ Hypoparathyroidism and rickets/osteomalacia: The recommended initial dose is 0.25 ㎍ of this medicine each morning. If there is not an adequate response in biochemical test results and clinical symptoms, increase the dose at intervals of 2 ~ 4 weeks. During dose determination, serum calcium levels should be measured at least twice weekly. Malabsorption sometimes occurs in patients with hypoparathyroidism, so higher doses may be necessary. ○ General information: After the optimal dose of this medicine has been determined, serum calcium levels should be measured once monthly. Blood samples for serum calcium measurement should be collected without a tourniquet. If serum calcium rises by 1 mg/dL (250 μmol/L) above the normal range of 9 ~ 11 mg/dL (2,250 ~ 2,750 μmol/L), or serum creatinine rises to 120 μmol/L or higher, promptly reduce the dose sufficiently or discontinue treatment until serum calcium returns to normal. Discontinuing supplemental calcium is also effective for rapidly normalizing serum calcium. Carefully consider reducing dietary calcium intake as well. During hypercalcemia, serum calcium and phosphorus levels should be measured daily. Once levels return to normal, continue treatment at a dose 0.25 ㎍ lower per day than the previous dose.

Children's dosage

○ Patients before the dialysis stage, children aged 36 months or older: The dose is 0.25 ㎍ of calcitriol daily and may be increased to 0.5 ㎍ daily if necessary. ○ Patients before the dialysis stage, children under 36 months: The recommended initial dose is 10 ~ 15 ng per kg of body weight daily.

Precautions

This medication should not be used in patients with diseases related to hypercalcemia or hypercalciuria. Patients allergic to this medication or its components should also avoid administration. Care should be taken in patients who are pregnant, breastfeeding, children under 36 months, or have a history of kidney stones. This medication is an active form of vitamin D, and overdose may lead to elevated serum calcium levels, resulting in various side effects. Therefore, during the use of this medication, serum calcium levels should be regularly checked to ensure they remain within normal range. Calcium intake should also be monitored to avoid exceeding the recommended daily amount, and any calcium supplements or dietary advice should be followed as per the physician's instructions. This medication may increase the risk of hypercalcemia when used concurrently with other vitamin D preparations or calcium-containing medications, so concurrent use should be avoided. Extra caution is needed when taken in combination with diuretics, digitalis preparations, and steroids. If pregnant or breastfeeding, careful consideration should be given to the impact of this medication on the fetus or newborn and should only be used after consulting a physician. Elderly patients may have reduced renal and liver function, so dosage should be adjusted, and side effects should be monitored closely. Overdose may cause symptoms such as vomiting, headache, anorexia, constipation, and in severe cases, to seek appropriate treatment at a medical facility. This medication should be stored in a cool place, away from light and moisture, and securely out of reach of children.

Side effects

  • nausea
  • diarrhea
  • appetite loss
  • constipation
  • vomiting
  • stomach discomfort
  • abdominal pain
  • thirst
  • abdominal cramps
  • paralytic ileus
Show 91 more
  • gastric pain
  • abdominal unease
  • epigastric pain
  • abdominal bloating
  • stomatitis
  • polydipsia and xerostomia
  • pancreatitis
  • metallic taste
  • restlessness
  • anxiety
  • insomnia
  • headache
  • apathy
  • drowsiness
  • manic psychosis
  • depression
  • coma
  • palpitations
  • venous thrombosis
  • hypertension
  • peripheral neuropathy
  • calcification around joints
  • bone pain
  • rhinorrhea
  • epistaxis
  • urinary tract infection
  • kidney stones
  • elevated AST
  • elevated ALT
  • elevated LDH
  • elevated BUN
  • elevated creatinine
  • increased blood uric acid
  • nephrocalcinosis
  • kidney stones
  • pruritus
  • urticaria
  • rash
  • skin dryness
  • conjunctivitis
  • conjunctival hyperemia
  • photophobia
  • fatigue
  • limb pain
  • polyuria
  • nocturia
  • dehydration
  • elevated ALP
  • hypermagnesemia
  • hypercalciuria
  • hyperphosphatemia
  • increased lymphocytes
  • elevated hematocrit
  • increased neutrophils
  • increased hemoglobin
  • malaise
  • abdominal pain
  • sensation of heat
  • fever accompanied by thirst
  • chest pain
  • menstrual disorders
  • facial flushing
  • lumbago
  • leg pain
  • cold sensation in limbs
  • edema
  • metastatic calcification
  • myasthenia
  • nutritional disorders
  • weight loss
  • high fever
  • myalgia
  • proteinuria
  • growth retardation
  • hypercalcemia
  • hypercholesterolemia
  • decreased libido
  • appetite loss
  • headache
  • vomiting
  • constipation
  • atrophic degeneration
  • weakness
  • weight loss
  • sensory disorders
  • fever accompanied by thirst
  • polyuria
  • dehydration
  • lethargy
  • growth suppression
  • urinary tract infection

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container that protects it from air, light, and moisture. Additionally, it is important to keep it in a cool place below 25 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Orange on top and white on the bottom, oval soft capsule

Package unit

30 capsules (10 capsules/PTP packaging x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.